Celastrol for Safety

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Patient Plus Urgent Care, Baton Rouge, LA
Safety
Celastrol - DietarySupplement
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This is an open label safety study that will not be blinded or placebo controlled. Purpose is to evaluate the safety of Celastrol in healthy men and women volunteers, between 18 and 40 years of age, over a 90-day period. Celastrol is different than Cholesterol. Cholesterol is a risk for heart disease. Celastrol is a natural occurring compound extracted from the root of Tripterygium wilfordii, a herb used in Chinese medicine.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 42 Secondary · Reporting Duration: 90 days

90 days
ALT (U/L)
AST (U/L)
Absolute Basophils (K/UL)
Absolute Eosinophils (K/UL)
Absolute Immature Granulocytes (K/UL)
Absolute Monocytes (K/UL)
Absolute Neutrophils (K/UL)
Absolute Nucleated RBCS (K/UL)
Albumin (G/DL)
Alkaline Phosphatase (U/L)
BUN (MG/DL)
Basophils (%)
Bilirubin, Total (MG/DL)
CALC A/G (Ratio)
CALC BUN/CREAT (Ratio)
CALC Globulin (G/DL)
Calcium (MG/DL)
Carbon Dioxide (MEQ/L)
Chloride (MEQ/L)
Creatine (MG/DL)
EKG evaluation
Eosinophils (%)
Glucose (MG/DL)
Hematocrit (%)
Hemoglobin (G/DL)
Immature Granulocytes (%)
Lymphocytes (%)
MCH (PG)
MCHC (G/DL)
MCV (fL)
MPV (fL)
Monocytes (%)
Neutrophils (%)
Nucleated RBCS (/100 WBC'S)
Platelet Count (K/UL)
Potassium (MEQ/L)
Protein, Total (G/DL)
RBC (M/UL)
RDW (%)
Sodium (MEQ/L)
The effect of celastrol on the function of the liver
WBC (K/UL)
eGFR (ML/MIN/1.73)

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Amount of Celastrol Administered
1 of 1
Experimental Treatment

35 Total Participants · 1 Treatment Group

Primary Treatment: Celastrol · No Placebo Group · N/A

Amount of Celastrol Administered
DietarySupplement
Experimental Group · 1 Intervention: Celastrol · Intervention Types: DietarySupplement

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 90 days
Closest Location: Patient Plus Urgent Care · Baton Rouge, LA
Photo of louisiana 1Photo of louisiana 2Photo of louisiana 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Safety
0 CompletedClinical Trials

Who is running the clinical trial?

Legend Labz, Inc.Lead Sponsor
1 Previous Clinical Trials
5 Total Patients Enrolled
Rubin Patel, MDPrincipal InvestigatorPatient Plus Urgent Care
1 Previous Clinical Trials
5 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a woman with a physical condition that makes it impossible to conceive.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References